A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer

PURPOSE: Preclinical tumor models show that chemotherapy has immune modulatory properties which can be exploited in the context of immunotherapy. The purpose of this study was to determine the feasibility and immunogenicity of combinations of such an immunomodulatory chemotherapeutic agent with immu...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncotarget
Huvudupphovsmän: Dijkgraaf, Eveline M., Santegoets, Saskia J.A.M., Reyners, An K.L., Goedemans, Renske, Nijman, Hans W., van Poelgeest, Mariëtte I.E., van Erkel, Arien R., Smit, Vincent T.H.B.M., Daemen, Toos A.H.H., van der Hoeven, Jacobus J.M., Melief, Cornelis J.M., Welters, Marij J.P., Kroep, Judith R., van der Burg, Sjoerd H.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Impact Journals LLC 2015
Ämnen:
Clinical Research Paper
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4741673/
https://ncbi.nlm.nih.gov/pubmed/26334096
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk